Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
SLGL | US
0.01
1.19%
Healthcare
Biotechnology
30/06/2024
17/10/2024
0.68
0.67
0.68
0.67
Sol-Gel Technologies Ltd. a clinical stage specialty pharmaceutical company focuses on identifying developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include Twyneo a novel once-daily non-antibiotic topical cream which has completed Phase III clinical trials for the treatment of acne vulgaris; Epsolay a once-daily topical cream that has completed Phase III clinical trials for the treatment of papulopustular rosacea; SGT-210 which is in Phase I clinical trial for the treatment of palmoplantar keratoderma; SGT-610 a rare disease for the treatment of Gorlin Syndrome which has completed Phase II clinical trials; and Erlotinib and Tapinarof to treat other rare skin indications. It is also involved in the development of generic topical dermatological drug products. The company has collaboration with Perrigo. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona Israel.
View LessLow Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Strong Operating Margin (> 25%)
Strong Revenue Growth (> 10%)
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
54.0%1 month
64.7%3 months
129.1%6 months
113.0%-
9.34
0.54
0.04
0.03
0.24
0.13
-
-16.52M
18.89M
18.89M
-
29.89
-
814.60
-35.85
0.95
0.69
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.11
Range1M
0.21
Range3M
0.55
Rel. volume
0.13
Price X volume
6.19K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Cocrystal Pharma Inc | COCP | Biotechnology | 2.04 | 20.75M | -7.27% | n/a | 10.24% |
Matinas BioPharma Holdings Inc | MTNB | Biotechnology | 4.08 | 20.66M | 4.88% | n/a | 16.97% |
BIOR | BIOR | Biotechnology | 0.5538 | 20.20M | -6.14% | n/a | -52.57% |
MONOPAR THERAPEUTICS | MNPR | Biotechnology | 5.71 | 20.10M | 8.56% | n/a | 0.00% |
Klotho Neurosciences Inc. | KLTO | Biotechnology | 0.59 | 20.06M | 5.06% | n/a | 0.00% |
Cadrenal Therapeutics Inc. Common Stock | CVKD | Biotechnology | 16.3 | 19.27M | 6.19% | n/a | 0.22% |
Minerva Neurosciences Inc | NERV | Biotechnology | 2.58 | 18.04M | -3.37% | n/a | -194.60% |
Cognition Therapeutics Inc. Common Stock | CGTX | Biotechnology | 0.4456 | 17.88M | -0.49% | n/a | 2.71% |
Inhibikase Therapeutics Inc. | IKT | Biotechnology | 2.35 | 17.54M | 21.13% | n/a | 3.49% |
Kazia Therapeutics Limited | KZIA | Biotechnology | 0.5269 | 17.54M | 58.04% | n/a | 6.82% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 12.6 | 19.19M | 0.80% | n/a | 204.46% |
ILAG | ILAG | Building Products & Equipment | 0.98 | 17.70M | -3.92% | n/a | 5.48% |
Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 0.5763 | 8.36M | -11.91% | 0.04 | 16.03% |
Forza X1 Inc | FRZA | Recreational Vehicles | 0.2111 | 3.79M | 2.93% | n/a | 0.97% |
EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.04 | 2.71M | -4.59% | n/a | 9.62% |
Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.0114 | 1.02M | 14.00% | n/a | -37.05% |
Winnebago Industries Inc | WGO | Recreational Vehicles | 60.16 | 0 | -0.43% | n/a | |
Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 4.3 | 0 | 2.14% | n/a | |
Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.535 | 0 | 7.00% | n/a | |
Urban One Inc | UONEK | Broadcasting - Radio | 1.07 | 0 | 1.90% | n/a |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | 0.24 | 0.53 | Cheaper |
Ent. to Revenue | 0.13 | 4,005.99 | Cheaper |
PE Ratio | - | 40.42 | - |
Price to Book | 0.54 | 15.30 | Cheaper |
Dividend Yield | - | 2.20 | - |
Std. Deviation (3M) | 129.14 | 72.92 | Riskier |
Debt to Equity | 0.04 | -1.24 | Expensive |
Debt to Assets | 0.03 | 0.25 | Cheaper |
Market Cap | 18.89M | 3.78B | Emerging |